Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080006 | 0.87 | NQO2 (0.47) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL8546692 | 0.86 | CYP1A2 (0.50) | CYP1A2KDM4EMEN1KMT2ACYP3A4 | |
| SCHEMBL27300635 | 0.85 | KDM4E (0.47) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL27292842 | 0.84 | KDM4E (0.46) | KDM4E | |
| SCHEMBL6588938 | 0.83 | ALOX15 (0.55) | KDM4EMEN1KMT2AMAPT | |
| SCHEMBL27317054 | 0.80 | PDE10A (0.44) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL165083 | 0.79 | KDM4E (0.49) | CYP1A2KDM4EMEN1KMT2ACYP3A4 | |
| SCHEMBL9319008 | 0.78 | TNF (0.50) | CYP1A2KDM4EMEN1KMT2AMAPT | |
| SCHEMBL2783408 | 0.78 | CYP1A2 (0.59) | CYP1A2KDM4EMEN1KMT2ANPC1 | |
| SCHEMBL163381 | 0.78 | SMN1; SMN2 (0.53) | CYP1A2KDM4EMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709503-B2 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1664025-B1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| EP-1664025-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026149-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| EP-0714393-B1 | THIAZOLES AS ANTIVIRAL | PFIZER (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5789408-A | Antiviral thiazoles | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | PEF1, PEPD, PELP1 | CYP1A2 675/4885KDM4E 3380/4885MEN1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.